SUBSCRIBE
SUBSCRIBE

Brandon May

Drug Development
Study: Drug Candidate Improves Brain Energy Metabolism in Parkinson’s, MS
Top-line results from the Phase II REPAIR trial show a gold nanocrystal suspension, CNM-Au8®, significantly improved brain energetic metabolism in patients with Parkinson’s disease and multiple sclerosis.
August 5, 2021
 · 
3 min read
 · 
Brandon May
Courtesy of nitpicker/Getty Images
Drug Development
Lung Cancer Drug Candidate Offers Patients Hope for Longer Life
The Phase III trial shows that PD-1 inhibitor Libtayo and platinum-doublet chemotherapy significantly improved OS compared with chemotherapy alone with locally advanced NSCLC.
August 5, 2021
 · 
2 min read
 · 
Brandon May
Al Drago/CQ Roll Call
Policy
Syntec Runs Afoul of FDA with Several GMP Infractions
Specifically, the FDA states Syntec has critical issues with how the pharmaceutical manufacturer handles active pharmaceutical ingredients, issues that may compromise the safety of the firm’s manufactured drugs.
August 4, 2021
 · 
2 min read
 · 
Brandon May
Business
Schrödinger and Zai Lab Partner in Innovative Precision Oncology Space
Schrödinger and Zai Lab have announced a worldwide development and commercialization collaboration to advance a novel oncology program targeting the DNA damage repair pathway.
August 4, 2021
 · 
2 min read
 · 
Brandon May
Courtesy Taljat David/Getty Images
Drug Development
FDA Lifts Partial Clinical Hold on Novartis’ Gene Therapy Trial for Spinal Muscular Atrophy
The FDA-initiated partial hold on Novartis’ gene therapy trial for spinal muscular atrophy has been lifted recently. Here’s everything you need to know about it.
August 3, 2021
 · 
3 min read
 · 
Brandon May
The performance of bevacizumab drug benefits the c
Drug Development
“Outlook” Good as Company’s AMD Drug Bevacizumab Shines in Phase III
Shares in the company climbed more than 30% premarket following the news of the study findings. The major reason is believed to be the performance of bevacizumab.
August 3, 2021
 · 
3 min read
 · 
Brandon May
Drug Development
Study: Servier’s TIBSOVO Prolongs Survival in Untreated IDH1-Mutated AML
Late-phase trial data show Servier’s TIBSOVO, in conjunction with chemotherapy azacitidine, prolonged event-free survival in adult patients with previously untreated IDH1-mutated acute myeloid leukemia.
August 2, 2021
 · 
3 min read
 · 
Brandon May
Pharm Country
Roivant Invests $200 Million in Immunovant to Advance Autoimmune Disorder Drug Candidate
The financing will be used to advance the company’s IMVT-1401 candidate across several different autoimmune disorder indications.
August 2, 2021
 · 
3 min read
 · 
Brandon May
Drug Development
New Drug Proves to Ease the Itch for Chronic Spontaneous Urticaria
Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.
July 30, 2021
 · 
2 min read
 · 
Brandon May
Craig F. Walker/The Boston Globe via Getty
Drug Development
Vertex Hopes to Channel CF Drug Successes into Other Therapies in the Pipeline
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
July 30, 2021
 · 
2 min read
 · 
Brandon May
Rafael Henrique/SOPA Images/LightRocket via Getty
Drug Development
Vaxart Sees Boosting Immunity with Oral Norovirus Vaccine Candidate, Hope for COVID-19
Clinical-stage biotech company Vaxart announced Thursday that a second dose of its oral norovirus vaccine boosted immunity in clinical trial participants who had previously received the vaccine more than a year prior.
July 29, 2021
 · 
3 min read
 · 
Brandon May
rafapress via shutterstock
Drug Development
Future of AstraZeneca’s Vaccine Business is Murky, But Seeks to Move Ahead with FDA Filing
AstraZeneca said in an earnings announcement on Thursday it will seek authorization for its COVID-19 vaccine in the U.S. sometime in the second half of this year.
July 29, 2021
 · 
3 min read
 · 
Brandon May
Business
DA32 Life Science SPAC Prices $200M IPO
Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO).
July 28, 2021
 · 
2 min read
 · 
Brandon May
Hand showing money in network. The concept of electronic money.
Business
IMIDomics, IgGenix and neuro42 Close Series A Rounds Worth Millions
Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.
July 28, 2021
 · 
2 min read
 · 
Brandon May
Sarah Silbiger/Getty Images
Drug Development
Biotech Companies Announce Big Drug Wins with FDA
Several biotech and biopharmaceutical companies have announced new wins with the U.S. Food and Drug Administration (FDA), with these wins ranging from Investigational New Drug (IND) application approvals for cancer treatment candidates to Fast Track Designations for investigational agents aimed toward opioid use disorder (OUD).
July 27, 2021
 · 
2 min read
 · 
Brandon May
Load More